Literature DB >> 7486458

Soft tissue abscesses associated with parenteral drug abuse: presentation, microbiology, and treatment.

J M Bergstein1, E J Baker, C Aprahamian, M Schein, D H Wittmann.   

Abstract

Abscess formation at the site of drug injection is the commonest infectious complication in drug addicts. This study characterizes the clinical presentation of the condition, its current microbiology, and treatment outcome. All patients presenting for treatment of soft tissue abscesses associated with parenteral drug abuse over a 21-month period were studied. Sixty-six patients with 70 subcutaneous abscesses after injection of cocaine (85%), heroin (5%), or unreported drugs (10%) were identified. Only 42% were febrile (T > 37.5 degrees C), 54 percent had leukocytosis, and 47 percent had wound fluctuance. Wound cultures (243 isolates in 57 patients) grew predominately anaerobes (143 isolates) and facultative gram-positive cocci (88 isolates). Twenty-six blood cultures were obtained, and five (19%) were positive, two with the same bacteria isolated from the wound. Of the patients tested, 29 percent were positive for hepatitis B surface antigen and 9 percent for HIV. Simple incision and drainage was effective in all cases. Classical signs and symptoms of infection and abscess formation may be absent in this patient population. Many of these patients carry other blood-borne infections which the health professional must guard against. Cocaine injection, and "mixed" aerobic-anaerobic infections predominated, in contrast to earlier reports, when narcotics and aerobes predominated. Simple incision and drainage is adequate treatment; antibiotics, when given, should cover gram-positive and anaerobic bacteria; gram-negative coverage is unnecessary.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7486458

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  9 in total

1.  The role of syringe filters in harm reduction among injection drug users.

Authors:  C Caflisch; J Wang; R Zbinden
Journal:  Am J Public Health       Date:  1999-08       Impact factor: 9.308

2.  Role of microbiological investigations in the management of non-perineal cutaneous abscesses.

Authors:  G Garcea; T Lloyd; M Jacobs; A Cope; A Swann; D Berry
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

3.  Skin and Soft Tissue Infections in Injection Drug Users.

Authors:  Patricia D. Brown; John R. Ebright
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

4.  Vertebral osteomyelitis and epidural abscess in a patient receiving enfuvirtide.

Authors:  J Portilla; V Boix; E Merino; S Reus; J M Seguí; I Lopez-Azkarreta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-03       Impact factor: 3.267

5.  Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California.

Authors:  Hsin Huang; Neil M Flynn; Jeff H King; Caroline Monchaud; Margaret Morita; Stuart H Cohen
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

Review 6.  A practical guide to the treatment of complicated skin and soft tissue infections.

Authors:  Horatio B Fung; Joanne Y Chang; Stephen Kuczynski
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Population-based surveillance of invasive group A streptococcal disease in British Columbia: 1996 to 1998.

Authors:  G L Bjorson; D W Scheifele; A Bell; A King
Journal:  Can J Infect Dis       Date:  2001-07

8.  Outbreak among drug users caused by a clonal strain of group A streptococcus.

Authors:  L M Böhlen; K Mühlemann; O Dubuis; C Aebi; M G Täuber
Journal:  Emerg Infect Dis       Date:  2000 Mar-Apr       Impact factor: 6.883

9.  Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis.

Authors:  Dominik Mertz; Nina Viktorin; Marcel Wolbers; Gerd Laifer; Bernd Leimenstoll; Ursula Fluckiger; Manuel Battegay
Journal:  BMC Infect Dis       Date:  2008-04-03       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.